GENFIT S.A.: GENFIT Reports Full-Year 2022 Financial Results

Cash, cash equivalents and current financial assets totaled €140.2 million1 as of December 31, 2022, expected to fund operations through third quarter 2024Transformative milestone expected towards end

Related Keywords

France , United States , United Kingdom , New York , Canada , Massachusetts , Switzerland , Cambridge , Cambridgeshire , Paris , France General , French , American , Pascal Prigent , Exchange Commission , Transition Services Agreement , Uncertainties Of The Company , Drug Administration , Euronext , Nasdaq , Pipeline Days , Drug Designation , Orphan Drug Designation , Liver Meeting , Child Pugh Score , Inborn Errors , Urea Cycle Disorders , Organic Acidemias , Investigational New Drug , Hepatic Encephalopathy , Statutory Auditors , Inventory Purchase Agreement , Nasdaq Global Select Market , Private Securities Litigation Reform Act , Registration Document , Year Business , Invasive Biomarkers , Metabolic Liver Disease , National Institutes , Genfit , Reports , Bull , Ear , 022 , Financial , Results , Rovides , Corporate , Update ,